Oculis Holding AG (OCS) Depreciation & Amortization - Total (2023 - 2026)
Oculis Holding AG (OCS) recorded quarterly Depreciation & Amortization - Total of $196658.7 in Q1 2026, down 0.52% quarter-over-quarter from $197684.8 in Q4 2025, and up 43.75% on a YoY basis from $136806.8 in Q1 2025.
Oculis Holding AG (OCS) Depreciation & Amortization - Total (2023 - 2026) Analysis & Trends
Oculis Holding AG's Depreciation & Amortization - Total history runs 4 years deep, the most recent figure standing at $196658.7 for Q1 2026.
- In Q1 2026, Depreciation & Amortization - Total rose 43.75% year-over-year to $196658.7; the TTM figure through Mar 2026 stood at $720851.8 (up 39.89% YoY), while the FY2025 annual figure was $683138.7, up 47.4% from the prior year.
- Depreciation & Amortization - Total was $196658.7 for Q1 2026 at Oculis Holding AG, down from $197684.8 in the prior quarter.
- In the past five years, Depreciation & Amortization - Total ranged from a high of $197684.8 in Q4 2025 to a low of $82647.1 in Q3 2023.
- Historically, Depreciation & Amortization - Total has averaged $135078.1 across 4 years, with a median of $136806.8 in 2025.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization - Total soared 70.38% in 2024, then jumped 34.94% in 2025.
- A 4-year view of Depreciation & Amortization - Total shows it stood at $83424.2 in 2023, then soared by 66.94% to $139265.7 in 2024, then soared by 41.95% to $197684.8 in 2025, then retreated by 0.52% to $196658.7 in 2026.
- The last three Depreciation & Amortization - Total figures came in at $196658.7 (Q1 2026), $197684.8 (Q4 2025), and $190016.6 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 196,658.72 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 196,658.72 |
| Dec 31, 2025 | 197,684.83 |
| Sep 30, 2025 | 190,016.65 |
| Jun 30, 2025 | 136,491.60 |
| Mar 31, 2025 | 136,806.82 |
| Dec 31, 2024 | 139,265.67 |
| Sep 30, 2024 | 140,813.28 |
| Jun 30, 2024 | 98,415.62 |
| Mar 31, 2024 | 83,634.81 |
| Dec 31, 2023 | 83,424.23 |
| Sep 30, 2023 | 82,647.14 |